JasMind Launches Global First Brain Physiology and Cognitive Function Assessment System, Files IPO Prospectus

Data shows that in ChinaAlzheimer's Disease(Alzheimer's disease, AD, commonly known as senile dementia) affects nearly 10 million patients. Its clinical manifestation is progressive cognitive impairment, during which mild cognitive impairment represents the earliest stage with clinical symptoms and constitutes the most critical window for early detection, diagnosis, prevention, and treatment of Alzheimer's disease. The "World Alzheimer Report 2015" indicates that the global economic burden of this disease is projected to reach $2.11 trillion by 2030 and soar to $7.45 trillion by 2050. Therefore, confronting Alzheimer's disease through early detection and early treatment has become an urgent clinical and social issue, as well as a pressing need in the field of public health in China.

Last December, byChengdu Jisi Mingzhi Technology Co., Ltd.(hereinafter referred to as “Jisi Mingzhi”)Independently Developed the World's First "Auxiliary Assessment System for Brain Physiology and Cognitive Functions"Approved for NMPA Medical Device Registration Certificate.This product is also the only internationally approved solution capable of providing objective, early auxiliary diagnosis for MCI.. By acquiring data from subjects at high speed (sampling frequency exceeding 1000 Hz) and with high precision (spatial error below 0.15°), based onEye Movement Behavioral Data Across Multiple Specific Eye-Tracking Paradigms, and comprehensively analyze and process eye-tracking parameters across various eye-tracking paradigms to derive assessment conclusions regarding cerebral physiological and cognitive functions.

Completed at West China Hospital of Sichuan University and the Affiliated Hospital of Chengdu University400 casesGCP Clinical Trials, with Accuracy Up to85%. PossessingSafe and free of side effects、Objective and Efficient、Easy to Operatesuch advantages. This will provide advanced technologies to address the limitations of existing clinical diagnostic methods, offering robust support for clinical diagnosis.

On Thursday, June 27, at 19:30, the 70th session of VCBeat Select New Product Review will feature Deng Tian, Director and General Manager of Beijing Jisi Mingzhi, the parent company, who will present"The World's First Assistive Assessment System for Brain Physiology and Cognitive Function"product promotion.

Figure: Jisi Mingzhi Brain Physiological and Cognitive Function Auxiliary Assessment System

This product is indicated for the auxiliary assessment of brain physiological and cognitive functions, as well as to assist physicians in diagnosing Mild Cognitive Impairment (MCI).

Consists of a main unit, computer, disposable eye mask, disposable pads, and software

Composed of a host unit (including a computer), disposable eye masks, disposable pads, and software.

The product features high stability and is suitable for use in high-altitude, high-salinity, and high-humidity environments.

The core team comprises three internationally renowned scientists from Peking University, Beijing Normal University, and Fudan University, who have long been engaged in neurobiology, cognitive neuroscience, and brain-inspired computing. Their academic research achievements cover top-tier specialized fields such as the neural mechanisms of cognitive functions, neural circuit function and neuromodulation, and computational neuroscience.

Ceiling saccade movement for assessing brain function based on behavioral evaluation, adhering to the research and development of domestically produced independent innovation products, has obtained 5 invention patents in China and abroad, with an additional 31 patents and software copyrights, and has received patent authorization in countries such as South Korea and Japan.

Since the product’s development, we have maintained close collaborations with numerous Grade A tertiary hospitals across China on neurodegenerative and psychiatric/psychological disorders, collecting high-precision eye-tracking data from diverse age groups, patients with various conditions, and healthy individuals, amassing a dataset comprising over 10,000 participant records; furthermore, we sustain long-term, stable partnerships with leading Chinese universities, research institutes, and national key laboratories.

Scan the QR code on the poster to add the assistant and reserve a spot for the live stream.

Director and General Manager, Beijing Jisi Mingzhi

10 years of experience in R&D and regulatory registration for innovative medical devices. Formerly served as Manager of the Regulatory Affairs Department at Infervision, achieving the world’s first regulatory approvals for an AI medical product in four countries and securing China’s first Class III medical device certificate for AI-based pulmonary nodule detection. Previously held positions as Director of Clinical Registration at Turing Microbiology (an IVD+AI company), and as Director of Clinical Registration and Head of Government Affairs at Wujiang Technology (a digital therapeutics company). Holds Bachelor’s and Master’s degrees in Control Science and Engineering from Beihang University.

Chengdu Jisi Mingzhi Technology Co., Ltd. was established in 2018 and co-founded by three internationally renowned scientists with extensive experience in brain science research. It is the first company in China to obtain approval for an innovative medical device based on eye-tracking technology. Its eye-tracking performance metrics have reached international advanced levels, and its clinical indications are at the global forefront. The company is dedicated to developing internationally leading brain function assessment products with original intellectual property rights, providing superior methods and tools for the early screening of neurological and psychiatric disorders. It has developed a 1000Hz high-precision eye tracker and algorithms, a 200Hz portable eye tracker, and eye-tracking algorithms for standard cameras under natural light conditions, all with independent Chinese intellectual property rights. The company is capable of providing healthcare partners with comprehensive services, including experimental paradigm design, eye-tracking data processing and modeling, and clinical study protocol design.

We have obtained three medical device registration certificates, including the world’s first registration certificate for an innovative medical device designed for brain assessment. This technology enables objective, early auxiliary diagnosis of mild cognitive impairment (MCI), contributing to the auxiliary diagnosis of clinical neurodegenerative diseases. We aim to be a pioneer in early, objective brain assessment and intervention technologies, benefiting a broader population.

“Artery Select New Product Debut” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower the milestone launch of every innovative medical product.

Scan the QR code below to contact the assistant and schedule a live stream viewing (if already added, please proactively message the assistant)

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Send a screenshot of the live stream to the assistant to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].